Trypanosoma brucei: Chemical evidence that cathepsin L is essential for survival and a relevant drug target

International Journal for Parasitology

Volumn 42, Issue 5, 2012, Pages 481-488

  Steverding, Dietmar ^a   Sexton, Darren W ^a   Wang, Xia ^a   Gehrke, Sebastian S ^b,d   Wagner, Gerd K ^b,d   Caffrey, Conor R ^c  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cysteine peptidase; Drug target; Protease inhibitor; Trypanosomiasis

Indexed keywords

2,3 OXIRANE 2,3 DICARBOXYLIC ACID 2 [(1 BENZYLCARBAMOYL 2 PHENYLETHYL)AMIDE] 3 [[2 (4 HYDROXYPHENYL)ETHYL]AMIDE]; BENZYLOXYCARBONYLPHENYLALANYLARGINYLDIAZOMETHYL KETONE; CAA 0225; CATHEPSIN B; CATHEPSIN L; CYSTEINE PROTEINASE INHIBITOR; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE METHYL ESTER; UNCLASSIFIED DRUG;

CONCENTRATION (COMPOSITION); DRUG DEVELOPMENT; ENZYME ACTIVITY; INHIBITION; PARASITE; PARASITIC DISEASE; PROTOZOAN; SURVIVAL;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL DEATH; CELL MEMBRANE PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME SPECIFICITY; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARASITE SURVIVAL; TRYPANOSOMA BRUCEI;

ANTIPROTOZOAL AGENTS; CATHEPSIN L; CELL SURVIVAL; MICROBIAL SENSITIVITY TESTS; PROTEASE INHIBITORS; PROTOZOAN PROTEINS; TRYPANOSOMA BRUCEI BRUCEI; VIRULENCE FACTORS;

PROTOZOA; TRYPANOSOMA BRUCEI;

EID: 84861227364     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2012.03.009     Document Type: Article

References (58)

1. Abdulla M.H., O'Brien T., Mackey Z.B., Sajid M., Grab D.J., McKerrow J.H. RNA interference of Trypanosoma brucei cathepsin B and L affects diseases progression in a mouse model. PLoS Negl. Trop. Dis. 2008, 2:e298.
2. Ashall F., Angliker H., Shaw E. Lysis of trypanosomes by peptidyl fluoromethyl ketones. Biochem. Biophys. Res. Commun. 1990, 170:923-929.
3. Baltz T., Baltz D., Giroud C., Crockett J. Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J. 1985, 4:1273-1277.
4. Barrett A.J., Kirschke H. Cathepsin B, cathepsin H, and cathepsin L. Methods Enzymol. 1981, 80:535-561.
5. Barrett M.P., Burchmore R.J., Stich A., Lazzari J.O., Frasch A.C., Cazzulo J.J., Krishna S. The trypanosomiases. Lancet 2003, 362:1469-1480.
6. Bogyo M., Verhelst S., Bellingrad-Dubouchaud V., Toba S., Greenbaum D. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem. Biol. 2000, 7:27-38.
7. Brun R., Blum J., Chappuis F., Burri C. Human African trypanosomiasis. Lancet 2010, 375:148-159.
8. Bryant C., Kerr I.D., Debnath M., Ang K.K., Ratnam J., Ferreira R.S., Jaishankar P., Zhao D., Arkin M.R., McKerrow J.H., Brinen L.S., Renslo A.R. Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasites cysteine proteases. Bioorg. Med. Chem. Lett. 2009, 19:6218-6221.
9. Buttle D.J., Murata M., Knight C.G., Barrett A.J. CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch. Biochem. Biophys. 1991, 199:377-380.
10. Caffrey C.R., Steverding D. Kinetoplastid papain-like cysteine peptidases. Mol. Biochem. Parasitol. 2009, 167:12-19.
11. Caffrey C.R., Scory S., Steverding D. Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr. Drug Targets 2000, 1:155-162.
12. Caffrey C.R., Hansell E., Lucas K.D., Brinen L.S., Alvarez Hernandez A., Cheng J., Gwaltney S.L., Roush W.R., Stierhof Y.-D., Bogyo M., Steverding D., McKerrow J.H. Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. Mol. Biochem. Parasitol. 2001, 118:61-73.
13. Caffrey C.R., Lima A.-P., Steverding D. Cysteine peptidases of kinetoplastid parasites. Adv. Exp. Med. Biol. 2011, 712:84-99.
14. Chen Y.T., Brinen L.S., Kerr I.D., Hansell E., Doyle P.S., McKerrow J.H., Roush W.R. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. PLoS Negl. Trop. Dis. 2010, 4:e825.
15. Delespaux V., de Koning H.P. Drugs and drug resistance in African trypanosomiasis. Drug Resist. Updat. 2007, 10:30-50.
16. Fairlamb A.H. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol. 2003, 19:488-494.
17. Fairlamb A.H., Henderson G.B., Bacchi C.J., Cerami A. In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Mol. Biochem. Parasitol. 1987, 24:185-191.
18. Fedorov Y., Anderson E.M., Birmingham A., Reynolds A., Karpilow J., Robinson K., Leake D., Marshall W.S., Khvorova A. Off-target effects by siRNA can induce toxic phenotype. RNA 2006, 12:1188-1196.
19. Grab D.J., Wells C.W., Shaw M.K., Webster P., Russo D.C.W. Endocytosed transferrin in African trypanosomes is delivered to lysosomes and may not be recycled. Eur. J. Cell Biol. 1992, 59:398-404.
20. Hirumi H., Hirumi K., Doyle J.J., Cross G.A.M. In vitro cloning of animal-infective bloodstream forms of Trypanosoma brucei. Parasitology 1980, 80:371-382.
21. 50 in studies of drug resistance of malaria parasites. Acta Trop. 1993, 55:257-261.
22. Jackson A.L., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., Li B., Cavet G., Linsley P.S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 2003, 21:635-637.
23. Jaishankar P., Hansell E., Zhao D.M., Doyle P.S., McKerrow J.H., Renslo A.R. Potency and selectivity of P2/P3-modified inhibitors of cysteine proteases from trypanosomes. Bioorg. Med. Chem. Lett. 2008, 18:624-628.
24. James K.E., Asgian J.L., Li Z.Z., Ekici O.D., Rubin J.R., Mikolajczyk J., Salvesen G.S., Powers J.C. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8. J. Med. Chem. 2004, 47:1553-1574.
25. Kerr I.D., Lee J.H., Farady C.J., Marion R., Rickert M., Sajid M., Pandey K.C., Caffrey C.R., Legac J., Hansell E., McKerrow J.H., Craik C.S., Rosenthal P.J., Brinen L.S. Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J. Biol. Chem. 2009, 284:25697-25703.
26. Kerr I.D., Wu P., Marion-Tsukamaki R., Mackey Z.B., Brinen L.S. Crystal structures of TbCatB and rhodesain, potential chemotherapeutic targets and major cysteine proteases of Trypanosoma brucei. PLoS Negl. Trop. Dis. 2010, 4:e701.
27. Lonsdale-Eccles J.D., Grab D.J. Lysosomal and non-lysosomal peptidyl hydrolases of the bloodstream forms of Trypanosoma brucei brucei. Eur. J. Biochem. 1987, 169:467-475.
28. Mackey Z.B., O'Brien T.C., Greenbaum D.C., Blank R.B., McKerrow J.H. A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei. J. Biol. Chem. 2004, 279:48426-48433.
29. Mallari J.P., Shelat A., Kosinski A., Caffrey C.R., Connelly M., Zhu F., McKerrow J.H., Guy R.K. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg. Med. Chem. Lett. 2008, 18:2883-2885.
30. Mallari J.P., Shelat A.A., Obrien T., Caffrey C.R., Kosinski A., Connelly M., Harbut M., Greenbaum D., McKerrow J.H., Guy R.K. Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J. Med. Chem. 2008, 51:545-552.
31. Mallari J.P., Shelat A.A., Kosinski A., Caffrey C.R., Connelly M., Zhu F., McKerrow J.H., Guy R.K. Structure-guided development of selective TbcatB inhibitors. J. Med. Chem. 2009, 52:6489-6493.
32. Matovu E., Seebeck T., Enyaru J.C., Kaminsky R. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect. 2001, 3:763-770.
33. Montaser M., Lalmanach G., Mach L. CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells. Biol. Chem. 2002, 383:1305-1308.
34. Morty R.E., Lonsdale-Eccles J.D., Morehead J., Caler E.V., Mentele R., Auerswald E.A., Coetzer T.H.T., Andrews N.W., Burleigh B.A. Oligopeptidase B from Trypanosoma brucei, a new member of an emerging subgroup of serine oligopeptidases. J. Biol. Chem. 1999, 274:26149-26156.
35. Murata M., Miyashita S., Yokoo C., Tamai M., Hanada K., Hatayama K., Towatari T., Nikawa T., Katunuma N. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett. 1991, 280:307-310.
36. Nkemngu N.J., Grande R., Hansell E., McKerrow J.H., Caffrey C.R., Steverding D. Improved trypanocidal activities of cathepsin L inhibitors. Int. J. Antimicrob. Agents 2003, 22:155-159.
37. North M.J., Coombs G.H., Barry J.D. A comparative study of the proteolytic enzymes of Trypanosoma brucei, T. equiperdum, T. evansi, T. vivax, Leishmania tarentolae and Crithidia fasciculate. Mol. Biochem. Parasitol. 1983, 9:161-180.
38. North M.J., Mottram J.C., Coombs G.H. Cysteine proteinases of parasitic protozoa. Parasitol. Today 1990, 6:270-275.
39. O'Brien T.C., Mackey Z.B., Fetter R.D., Choe Y., O'Donoghue A.J., Zhou M., Craik C.S., Caffrey C.R., McKerrow J.H. A parasite cysteine protease is key to host degradation and iron acquisition. J. Biol. Chem. 2008, 283:28934-28943.
40. Pamer E.G., So M., Davis C.E. Identification of a developmentally regulated cysteine protease of Trypanosoma brucei. Mol. Biochem. Parasitol. 1989, 33:27-32.
41. Pisoni R.L., Acker T.L., Lisowski K.M., Lemons R.M., Thoene J.G. A cysteine-specific lysosomal transport system provides a major route for the delivery of thiol to human fibroblast lysosomes: possible role in supporting lysosomal proteolysis. J. Cell Biol. 1990, 110:327-335.
42. Ramalingam B., Neuburger M., Pfaltz A. Synthesis of chiral C2-symmetric methylene- and boron-bridged bis(imidazolines). Synthesis 2007, 572-582.
43. Rawlings N.D., Barrett A.J., Bateman A. MEROPS: the peptidase database. Nucleic Acids Res. 2010, 38:D227-D233.
44. Robertson C.D., North M.J., Lockwood B.C., Coombs G.H. Analysis of the proteinases of Trypanosoma brucei. J. Gen. Microbiol. 1990, 136:921-925.
45. 2. Exp. Parasitol. 1999, 91:327-333.
46. Shaw E. Cysteinyl proteinases and their selective inactivation. Adv. Enzymol. Relat. Areas Mol. Biol. 1990, 63:271-347.
47. Steverding D. The history of African trypanosomiasis. Parasit. Vectors 2008, 1:3.
48. Steverding D. The development of drugs for treatment of sleeping sickness: a historical review. Parasit. Vectors 2010, 3:15.
49. Steverding D. The cathepsin B-selective inhibitors CA-074 and CA-074Me inactivate cathepsin L under reducing conditions. Open Enzym. Inhib. J. 2011, 4:11-16.
50. Steverding D., Stierhof Y.-D., Fuchs H., Tauber R., Overath P. Transferrin-binding protein complex is the receptor for transferrin uptake in Trypanosoma brucei. J. Cell Biol. 1995, 131:1173-1182.
51. Steverding D., Wang X., Sexton D.W. The trypanocidal effect of NO-releasing agents is not due to inhibition of the major cysteine proteinase in Trypanosoma brucei. Parasitol. Res. 2009, 105:1333-1338.
52. Takahashi K., Ueno T., Tanida I., Minematsu-Ikeguchi N., Murata M., Kominami E. Characterization of CAA0225, a novel inhibitor specific for cathepsin L, as a probe for autophagic proteolysis. Biol. Pharm. Bull. 2009, 32:475-479.
53. Tamai M., Yokoo C., Murata M., Oguma K., Sota K., Sota E., Kanaoka Y. Efficient synthetic method for ethyl(+)-(2S,3S)-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-2-oxiranecarboxylate (EST), a new inhibitor of cysteine proteinases. Chem. Pharm. Bull. 1987, 35:1098-1104.
54. Troeberg L., Pike R.N., Morty R.E., Berry R.K., Coetzer T.H.T., Lonsdale-Eccles J.D. Proteases from Trypanosoma brucei brucei. Purification, characterisation and interactions with host regulatory molecules. Eur. J. Biochem. 1996, 238:728-736.
55. Troeberg L., Morty R.E., Pike R.N., Lonsdale-Eccles J.D., Palmer J.T., McKerrow J.H., Coetzer T.H.T. Cysteine proteinase inhibitors kill cultured bloodstream forms of Trypanosoma brucei brucei. Exp. Parasitol. 1999, 91:349-355.
56. Vicik R., Hoerr V., Glaser M., Schultheis M., Hansell E., McKerrow J.H., Holzgrabe U., Caffrey C.R., Ponte-Sucre A., Moll H., Stich A., Schirmeister T. Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents. Bioorg. Med. Chem. Lett. 2006, 16:2753-2757.
57. Webster P., Griffiths G. A novel method for mean cell-volume estimation. J. Microsc. 1994, 174:85-92.
58. World Health Organization, 2010. African trypanosomiasis (sleeping sickness). World Health Org. Fact Sheet 259.